Comparing the current results to its competitors, Adlai Nortye Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Adlai Nortye Ltd's competitors' average revenue growth of 7.62 %, achieved in the same quarter.
Adlai Nortye Ltd's Comment on Competition and Industry Peers
The company operates in a highly competitive environment characterized by rapid technological change, with competitors potentially developing similar, more advanced, or more effective therapies. This competitive pressure is especially pronounced during the early stages of drug development. The company may encounter patent infringement issues, which could result in costly and time-consuming legal proceedings. Additionally, the company faces risks related to the protection of its intellectual property and trade secrets, including potential breaches by third parties such as contract research organizations, academic partners, funding organizations, and licensing or collaboration partners.
May 24, 2024
Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising preliminary data at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. The data pertains to the use of their innovative cancer therapy, AN0025, in combination with definitive chemoradiotherapy (dCRT) for patients with unresectable locally advanced or locally recurrent esophageal cancer (EC).Esophageal cancer is a serious and often fatal disease, and effective treatment options for patients with advanced or recurrent forms are limited. Adlai Nortye s AN0025 therapy aims...
May 22, 2024
Adlai Nortye Initiates Phase II Clinical Trial of Palupiprant for Locally Advanced Rectal Cancer Treatment Singapore, North Brunswick, NJ, and Hangzhou, China, May 22, 2024 Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology firm specializing in cutting-edge cancer treatments, is pleased to announce the initiation of its Phase II clinical trial for palupiprant (AN0025), a promising small molecule prostaglandin E receptor 4 (EP4) antagonist. The first patient has been successfully dosed in this trial, known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery), aimed at improving treatment outcomes for patients with locally advanced rectal cancer.The ARTEMIS trial is a...
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
Sources:
Adlai Nortye Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adlai Nortye Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
